PROCEPT BioRobotics (NASDAQ:PRCT) Stock Price Target Raised at UBS Group

PROCEPT BioRobotics (NASDAQ:PRCT) had its price objective boosted by analysts at UBS Group from $20.00 to $21.00 in a research report issued to clients and investors on Thursday, Benzinga reports. The brokerage currently has a “neutral” rating on the stock. UBS Group‘s target price suggests a potential upside of 3.60% from the company’s previous close.

Several other brokerages have also commented on PRCT. Jefferies Financial Group reiterated a “hold” rating and issued a $20.00 target price on shares of PROCEPT BioRobotics in a research report on Wednesday, August 5th. Wells Fargo & Company cut PROCEPT BioRobotics from an “overweight” rating to an “equal weight” rating and set a $19.00 target price on the stock. in a research report on Wednesday, August 5th. Truist Financial set a $21.00 price target on shares of PROCEPT BioRobotics in a research report on Wednesday, August 5th. Leerink Partners lifted their target price on PROCEPT BioRobotics from $20.00 to $22.00 and gave the stock a “market perform” rating in a report on Thursday. Finally, Oppenheimer restated a “market perform” rating on shares of PROCEPT BioRobotics in a research report on Wednesday, September 9th. Three equities research analysts have rated the stock with a Strong Buy rating, two have given a Buy rating, nine have assigned a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, PROCEPT BioRobotics currently has a consensus rating of “Hold” and a consensus target price of $25.00.

PROCEPT BioRobotics Stock Down 6.4%

NASDAQ PRCT traded down $1.39 on Thursday, reaching $20.27. The company had a trading volume of 3,108,199 shares, compared to its average volume of 1,509,829. The firm has a market capitalization of $1.16 billion, a PE ratio of -10.45 and a beta of 0.88. The firm has a 50-day moving average of $19.34 and a 200-day moving average of $23.23. The company has a debt-to-equity ratio of 0.15, a current ratio of 6.55 and a quick ratio of 5.35. PROCEPT BioRobotics has a 1 year low of $16.67 and a 1 year high of $38.11.

PROCEPT BioRobotics (NASDAQ:PRCT) last posted its quarterly earnings data on Wednesday, November 4th. The company reported ($0.46) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.07). PROCEPT BioRobotics had a negative net margin of 32.53% and a negative return on equity of 30.62%. The firm had revenue of $98.29 million during the quarter, compared to analysts’ expectations of $100.52 million. During the same period in the previous year, the company earned ($0.38) earnings per share. The business’s quarterly revenue was up 18.0% on a year-over-year basis. On average, equities research analysts anticipate that PROCEPT BioRobotics will post -1.67 EPS for the current fiscal year.

Insider Buying and Selling

In related news, CEO Larry Wood purchased 23,900 shares of the stock in a transaction on Friday, August 7th. The shares were bought at an average price of $20.85 per share, for a total transaction of $498,315.00. Following the completion of the acquisition, the chief executive officer directly owned 23,900 shares in the company, valued at approximately $498,315. This trade represents a ∞ increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders sold a total of 1,043 shares of company stock worth $21,851 in the last 90 days. Company insiders own 4.00% of the company’s stock.

Hedge Funds Weigh In On PROCEPT BioRobotics

Large investors have recently made changes to their positions in the business. BlackRock Inc. bought a new position in PROCEPT BioRobotics during the second quarter worth $109,961,000. Jupiter Topco LLC acquired a new stake in shares of PROCEPT BioRobotics in the 2nd quarter valued at $24,914,000. William Blair Investment Management LLC bought a new stake in PROCEPT BioRobotics during the 2nd quarter worth approximately $16,020,000. Bank of America Corp DE acquired a new stake in PROCEPT BioRobotics in the 2nd quarter valued at about $11,656,000. Finally, CPMG Inc bought a new stake in shares of PROCEPT BioRobotics during the first quarter worth $10,661,000. Institutional investors and hedge funds own 89.46% of the company’s stock.

PROCEPT BioRobotics News Roundup

Here are the key news stories impacting PROCEPT BioRobotics this week:

• Positive Sentiment: Revenue rose 18% year over year, and PROCEPT reaffirmed its 2026 financial guidance, providing a positive counterpoint to the quarterly earnings miss. Company results and guidance
• Neutral Sentiment: Leerink Partners raised its price target from $20 to $22 but kept a Market Perform rating, signaling limited near-term conviction despite the higher target. Leerink Partners ratings
• Negative Sentiment: PRCT reported a quarterly loss of $0.46 per share, wider than the $0.39 loss analysts expected and the $0.38 loss a year earlier. Revenue of $98.3 million also fell short of the roughly $100.5 million consensus. The earnings and sales misses likely weighed on the shares. Q3 results and estimates

About PROCEPT BioRobotics

PROCEPT BioRobotics Corporation is a medical technology company focused on developing and commercializing robotic solutions for the treatment of benign prostatic hyperplasia (BPH), a noncancerous enlargement of the prostate that can cause urinary symptoms. The company’s technology is designed to provide a minimally invasive alternative to conventional surgical procedures.

Its primary product is the AquaBeam Robotic System, which uses image guidance, robotic assistance and a high-velocity waterjet to remove targeted prostate tissue.